Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
BSF Enterprise PLC on Wednesday announced a narrowed loss as it remains dedicated to advancing its portfolio, which focuses on sustainable tissue-engineered materials.
The London-based biotech company is the owner of companies including 3D Bio-Tissues, a pioneer of lab-grown tissues, as well as the corneal replacement company Kerato.
The company said pretax loss narrowed to £793,963 in the six months to March 31, from £864,775 a year prior.
Revenue fell 62% to £20,559 from £54,295. Grant income jumped to £67,823 from £3,779.
Cost of sales came down 81% to £5,065 from £25,997.
Looking ahead, BSF Enterprise said: ‘BSF Enterprise remains dedicated to advancing its portfolio of sustainable tissue-engineered materials and strategic collaborations. With significant progress in lab-grown leather commercialisation, partnerships with industry leaders, and successful financing initiatives completed in 2025, the group is well-positioned for continued growth, innovation, and value creation in the year ahead.’
BSF Enterprise shares were 0.7% higher at 2.27 pence each on Wednesday afternoon in London.
Copyright 2025 Alliance News Ltd. All Rights Reserved.